Search Results
Your search for A matches 32982 pages
Showing 6251 - 6300
Nabil F. Saba, MD, on Head and Neck Squamous Cell Carcinoma: Phase II Findings on Pembrolizumab and Cabozantinib
Nabil F. Saba, MD, of Winship Cancer Institute of Emory University, discusses new data from a trial of pembrolizumab and cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma. The study met its primary endpoint of overall response rate. The regimen was well...
Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss the 24-month findings from the phase III EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and ...
Timothy J. Whelan, MD: When Can Radiotherapy Be Avoided After Breast-Conserving Surgery?
Timothy J. Whelan, MD, of McMaster University and Hamilton Health Sciences, discusses findings from the LUMINA study, which found that women aged 55 or older who had grade 1–2 T1N0 luminal A breast cancer following breast-conserving surgery and were treated with endocrine therapy alone had very low ...
Neal D. Shore, MD, on Germline Genetic Testing and Its Impact on Prostate Cancer Clinical Decision-Making
Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses his study findings, showing that germline genetic testing influenced care for patients with prostate cancer. Men whose genetic test was positive for a pathogenic germline variant received more recommendations for changes to...
Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay
Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use...
Michael J. Overman, MD, and Jeanne Tie, MBChB, MD, on Colon Cancer: Guiding Adjuvant Chemotherapy With ctDNA
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Jeanne Tie, MBChB, MD, of Peter MacCallum Cancer Centre, discuss results from the DYNAMIC trial, in which a circulating tumor DNA (ctDNA)-guided approach reduced the use of adjuvant chemotherapy without compromising...
Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel...
Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent...
Capecitabine Plus Temozolomide vs Temozolomide Alone in Advanced Pancreatic Neuroendocrine Tumors
In the updated final analysis of the phase II ECOG-ACRIN E2211 trial, patients with advanced pancreatic neuroendocrine tumors experienced a significant improvement in progression-free survival with capecitabine plus temozolomide over temozolomide alone.1 Although the 5-month difference in overall...
FLT3 Inhibitor Crenolanib in Combination With Chemotherapy for Newly Diagnosed Patients With FLT3-Mutant AML
Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, and colleagues presented the long-term results of a phase II clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for the treatment of adults with newly diagnosed ...
Weekly Electronic Reporting of Symptoms Improved Outcomes in Patients With Advanced Cancer
People with advanced cancer who communicated their symptoms weekly using an electronic survey had about one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a ...
mFOLFOXIRI/Panitumumab vs mFOLFOX/Panitumumab for the Initial Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer
In an Italian phase III trial (TRIPLETE) presented at the 2022 ASCO Annual Meeting (Abstract LBA3505) and simultaneously published in the Journal of Clinical Oncology, Rossini et al found that mFOLFOXIRI (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus panitumumab did not...
Ramucirumab/Pembrolizumab vs Standard of Care in Patients With Advanced NSCLC Previously Treated With Immune Checkpoint Inhibitors
In the phase II Lung-MAP substudy S1800A presented at the 2022 ASCO Annual Meeting (Abstract 9004) and simultaneously reported in the Journal of Clinical Oncology, Karen L. Reckamp, MD, and colleagues found that the combination of ramucirumab and pembrolizumab improved overall survival vs...
Patient-Facing Screening Tool Could Increase Detection of Individuals With Lynch Syndrome
Nearly 1 million people in the United States are affected by Lynch syndrome, a hereditary cancer condition with markedly elevated risk of gastrointestinal, endometrial, and other cancers. Most of them, however, are unaware of it, or find out only after they have developed cancer. A screening...
Immunotherapy Combination in Newly Diagnosed Glioblastoma
A novel combination of two experimental cancer immunotherapy agents along with an immune checkpoint blocker elicited robust immune responses in patients with newly diagnosed glioblastoma brain tumors, according to a presentation of interim, 2-year follow-up clinical trial data given by David...
Three-Arm First-Line Chemoimmunotherapy Study in Patients With Metastatic Pancreatic Cancer
Combinations of chemotherapy and immunotherapy showed activity in patients with metastatic pancreatic cancer, according to findings from a national, randomized clinical trial led and sponsored by the Parker Institute for Cancer Immunotherapy. The results of the small trial were presented by Padrón...
Study Finds Genetic Mutations Differ Across Younger and Older Patients With Breast Cancer
Women younger than age 40 with advanced breast cancer often experience more aggressive disease and worse prognoses than their older counterparts. Knowing which types of genetic mutations these patients tend to have may inform treatment strategies and improve outcomes. In a recent study, researchers ...
Did the ACA’S Medicaid Expansion Affect Cancer Clinical Trial Enrollment?
Researchers from the SWOG Cancer Research Network, a clinical trials group funded by the National Cancer Institute (NCI), found that the Affordable Care Act’s (ACA) expansion of Medicaid insurance in 2014 was followed by a significant increase in the proportion of patients enrolling in SWOG trials...
Biomarker Guidance May Allow Patients Aged 55 or Older With Low-Grade Luminal A–Type Breast Cancer to Avoid Radiation Therapy
Based on guidance from biomarker screening, patients with low-grade luminal A–type breast cancer aged 55 and older may need endocrine therapy alone following breast-conserving surgery and may be able to avoid radiation therapy entirely, according to new research findings presented by Timothy Joseph ...
Georgina V. Long, MD, PhD, on Melanoma: Distant Metastasis–Free Survival With Adjuvant Pembrolizumab
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses phase III findings from the KEYNOTE-716 study. The trial showed that compared with placebo, adjuvant pembrolizumab significantly improved distant metastasis–free survival in patients with resected...
Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib
Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus capivasertib in women with metastatic estrogen receptor–positive breast cancer whose disease had...
Stephen M. Ansell, PhD, MD, on Hodgkin Lymphoma: An Updated Analysis on First-Line Brentuximab Vedotin Plus Chemotherapy
Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin,...
Ursula A. Matulonis, MD, and Nicoletta Colombo, MD, on Ovarian Cancer: Overall Survival Data on Relacorilant Plus Nab-Paclitaxel
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with ...
Neoadjuvant Immunotherapy May Improve Survival for Patients With Soft-Tissue Sarcoma
In a phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), Keung et al reported at the 2022 ASCO Annual Meeting (Abstract LBA11501)....
Researchers Examine Racial Differences in Treatment and Outcomes of First-Line Therapies for Kidney Cancer
Black and White patients treated with similar first-line therapies for advanced kidney cancer experienced similar outcomes, but different response rates, according to research from Fox Chase Cancer Center presented by Daniel Geynisman, MD, at the 2022 ASCO Annual Meeting (Abstract 4548). “This was...
Study Examines Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer
Although women of African descent experience a higher incidence and mortality from triple-negative breast cancer than women of other races or ethnicities, research findings presented by Hall et al at the 2022 ASCO Annual Meeting showed that the magnitude of gene-specific risks of triple-negative...
Study Shows Children Whose Parents Have a Cancer History Have Increased Unmet Economic Needs in Food, Housing, and Transportation
In a new large study led by researchers at the American Cancer Society, findings showed that parental cancer is associated with a greater likelihood of family-level food insecurity, financial worry about housing costs and other monthly bills, and transportation barriers to medical care for children ...
'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly
Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the ...
Courtney D. DiNardo, MD, MSCE, and Jorge E. Cortes, MD, on CML: New Efficacy and Safety Results for Asciminib
Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discuss phase III results from the ASCEMBL trial, which showed that after more than 2 years of follow-up, asciminib continued to yield...
Lisa A. Carey, MD, and Hope S. Rugo, MD, on Advanced Breast Cancer: New Data on Sacituzumab Govitecan-hziy vs Treatment of Physician’s Choice
Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss phase III results from the TROPiCS-02 trial. This study showed that...
Dabrafenib Plus Trametinib Improve Overall Response Rates vs Standard-of-Care Chemotherapy in Pediatric Patients With Low-Grade Gliomas
The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600...
Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination...
Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials
Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of...
Paul G. Richardson, MD, on Multiple Myeloma: New Data on Lenalidomide, Bortezomib, and Dexamethasone, With or Without ASCT
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III findings from the DETERMINATION trial, which showed that, for patients with newly diagnosed multiple myeloma, lenalidomide, bortezomib, and dexamethasone (RVd) with or without autologous stem cell transplant (ASCT) and...
Brentuximab Vedotin Plus Chemotherapy vs Chemotherapy Alone for Pediatric Patients With Hodgkin Lymphoma
A new study has shown that a combination of brentuximab vedotin and standard chemotherapy is safe and appears to be more effective than standard chemotherapy in pediatric patients up to age 21 with newly diagnosed high-risk Hodgkin lymphoma. Findings from the Children's Oncology Group phase III...
Racial/Ethnic Disparities and Cardiovascular Mortality Among Cancer Survivors
A recent large national study showed the mortality risk from cardiovascular disease differs considerably among cancer survivors by race/ethnicity and cancer types. The findings are being presented by Sung et al at the 2022 ASCO Annual Meeting (Abstract 12075). In this study, lead author Hyuna Sung, ...
Study Offers Guidance for Future Trials of Adjuvant Therapy for Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer
To fully evaluate hormone-blocking therapy following surgery for patients with early-stage high-risk hormone receptor–positive/HER2-negative breast cancer, researchers should continue to track patients for at least 5 years after the completion of active treatment, according to a study reported at...
Including ASCT as Part of Initial Therapy Improves Progression-Free Survival in Newly Diagnosed Patients With Multiple Myeloma
The use of autologous stem cell transplantation (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed patients with multiple myeloma compared with patients who received chemotherapy without an initial...
Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas
Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according to research presented by McCabe et al during the Plenary Session at the 2022 ASCO Annual Meeting...
Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer
The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor,...
Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer
The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who received mFOLFOX6 plus bevacizumab, according to findings presented during the Plenary Session by...
Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol
Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients with myelofibrosis, momelotinib was superior to danazol for symptom and spleen responses, as well as ...
Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine
Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine...
Endocrine Sensitivity Test Predicts Survival Benefit of Dose-Dense Chemotherapy for Patients With Hormone Receptor–Positive Breast Cancer
A new genomic test designed to measure the endocrine sensitivity of estrogen receptor–positive breast cancer has the potential to identify patients diagnosed with the disease who could benefit more from dose-dense chemotherapy—a regimen in which chemotherapy is administered more frequently than...
Study Reveals Racial Disparities in Guideline-Concordant Care for Patients With Early-Onset Colorectal Cancer
In a large national study, Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their White counterparts. Differences in health insurance coverage type, a modifiable factor, according to the findings, accounted for the largest identified contributor...
New Report Shows COVID-19 Pandemic Increased Cancer-Related Deaths in the United States
According to a new study led by researchers at the American Cancer Society, the COVID-19 pandemic increased the number of cancer-related deaths by 3.2% in the United States from 2019 to 2020. Compared to 2019, the monthly cancer-related mortality rate was higher in April 2020, when health-care...
Adagrasib Improves Outcomes in KRAS-Mutated NSCLC, Phase II Study Shows
Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of...
ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities
In a collaboration announced today, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the United Nations Sustainable Development Goals and WHO Global Action Plan on...
ctDNA May Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer
In patients with stage II colon cancer where cancer DNA was not present in the blood (as circulating tumor DNA, or ctDNA), adjuvant chemotherapy could be skipped without compromising recurrence-free survival. Conversely, for patients where ctDNA was present after surgery, the rate of recurrence...
Sacituzumab Govitecan-hziy Improves Progression-Free Survival in Endocrine-Resistant Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many prior therapies for hormone receptor–positive/HER2-negative metastatic breast cancer, according to...
